Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
305
resultados
Última actualización
14/07/2026 [08:22:00]
Resumen de: CN120064427A
The invention discloses a method for detecting spatial distribution of brain nucleic acid hydrolysate based on mass spectrum imaging and an analysis system.The method comprises the steps of sample preparation, mass spectrum imaging and spatial quantitative analysis of nucleic acid hydrolysate, specifically, a spray needle capillary tube with the diameter being 10-30 micrometers is adopted, the angle between a spray needle and a sample glass slide is adjusted to be 55-57 degrees, the height is 35-36.5 mm, and the sample glass slide is placed in the sample capillary tube; the method comprises the following steps: uniformly spraying a spray solvent on the surface of a brain slice, scanning the whole sample to obtain mass spectrum imaging data, extracting the ion strength of target objects corresponding to different brain regions according to the monitored ion mass-to-charge ratio of the nucleic acid hydrolysate, and obtaining the spatial distribution of the nucleic acid hydrolysate in the different brain regions of the brain; the analysis system can extract the ion strength of the target object corresponding to the different brain regions according to the obtained brain mass spectrum and the monitored ion mass-to-charge ratio of the target object, the spatial distribution of the target object in the different brain regions is obtained, and spatial difference analysis among different groups is completed.
Resumen de: AU2024398768A1
Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.
Resumen de: WO2026144428A1
Provided are an scFv antibody that specifically binds Aβ, an isolated nucleic acid encoding the antibody, a vector comprising the nucleic acid, a cell comprising the isolated nucleic acid or the vector, a method for preparing the scFv antibody that specifically binds Aβ, and a use of the scFv antibody that specifically binds Aβ in the preparation of a medicament for treating Alzheimer's disease.
Resumen de: AU2024411321A1
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
Resumen de: US20260194540A1
The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.
Resumen de: US20260194539A1
A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.
Resumen de: US20260191829A1
0000 Pharmaceutical compositions containing a dopamine Putamen reuptake inhibitor or a dopaminergic agonist, an adrenoceptor antagonist, and a pharmaceutically acceptable carrier, and methods for treating neurological diseases by administering the composition.
Resumen de: US20260194516A1
0000 The invention is based on a novel technology to identify inflammatory responsive elements (IREs) in a mesenchymal stromal cell (MSC) culture that allowed for the development of biomarkers, in particular CD55, CD146, CD271 and MSCA-1, or combinations thereof. The biomarkers of the invention are indicative for an immunomodulatory activity of an MSC. Consequently, the present invention pertains a first aspect, to a method for determining a presence or absence of an immunomodulatory activity of a mesenchymal stromal cell (MSC). Furthermore, in a second aspect, a method for the manufacture of an immunomodulatory preparation derived from an MSC with immunomodulatory activity is disclosed. In a third and fourth aspect, the invention pertains to an immunomodulatory preparation derived from an MSC with immunomodulatory activity and its medical use. In further aspects, the invention also pertains to methods for identifying an immunomodulatory population and an immunomodulatory subpopulation of MSCs with a known presence and/or expression of a biomarker respectively, and to an agent for determining a presence or absence of an immunomodulatory activity of an MSC.
Resumen de: US20260193314A1
A ratiometric fluorescent sensor constructed based on a G protein-coupled receptor and its construction method are provided. It is discovered that by introducing a mutation at the same amino acid site (the third amino acid of the N-terminal linker) on a GRAB sensor, the GRAB sensor can be endowed with excitation ratiometric properties. The sensor with excitation ratiometric properties have high pH sensitivity, are not limited by the sensor's own expression level or external hardware conditions, maintain high stability of fluorescence brightness, can minimize fluorescence interference caused by motion, can sensitively detect neurotransmitter release, and have the potential for in vivo quantitative detection of neurotransmitter concentration.
Resumen de: US20260196299A1
0000 Methods, systems, and kits are provided for assessing cardiorespiratory fitness and predicting cardiometabolic risk.
Resumen de: US20260191820A1
0000 Provided herein are methods and compositions utilizing a urolithin A agent and a fisetin agent for treatment of neurodegenerative diseases.
Resumen de: US20260193347A1
0000 The invention provides antibodies that specifically bind GPR158 and inhibit GAP activity of GPR158 via RGS7/Gβ5. The antibodies are useful in the diagnosis and treatment of affective disorders, mood disorders, and brain disorders.
Resumen de: US20260191428A1
0000 A tool for collection of exhaled breath includes a microreactor for capturing and concentrating target compounds in a gaseous sample, such as exhaled breath. An airflow of exhaled breath enters the interior of the microreactor, then contacts the central area of the microreactor and is redirected radially outwards, passing through microfluidic channels formed between micropillars, and exits the microreactor through a plurality of vent holes at the periphery. The micropillars are coated with a capture material, such as a reactive compound capable of forming adducts with carbonyl-containing VOCs. The captured target compounds may then be eluted from the micropillars and analyzed for detection of disease states or other purposes.
Resumen de: US20260186004A1
0000 It has been established that increased levels of lactylated of tau protein in the brain and CNS is associated with tauopathies and neurodegenerative diseases, and increased levels of lactylated lysine on tau protein has been established as a marked for AD. Compositions and methods for the detection and treatments of tauopathies have been developed. In some forms, the methods identify and quantify lactylated lysine on tau protein in a biological sample from a subject to diagnose a tauopathy, such as AD. In some forms, the methods identify a subject as having or at risk of having a tauopathy. In some forms, the methods include treating the tauopathy. Compositions to identify a tauopathy include lactylated tau binders, such as antibodies are also described. Compositions to treat or prevent a tauopathy, such as lactylated tau peptides having a defined lactyllysine, are also described.
Resumen de: WO2026142290A1
The present invention relates to a biomarker-specific binding probe and a use thereof. By introducing the probe into a nanopore, it is possible to accurately and rapidly detect the presence and abundance of a specific biomarker in a sample.
Resumen de: WO2026142185A1
In a surface-enhanced Raman scattering-based method for testing drug reactivity of cerebrovascular cells, a SERS substrate is manufactured. A SERS substrate array including a plurality of the SERS substrates is manufactured. Cells are cultured on the SERS substrate array. A drug is administered to the cultured cells. A Raman signal is measured from the cells to which the drug is administered. An optimal drug is selected from among the administered drugs on the basis of the measured Raman signal.
Resumen de: US20260183364A1
The present disclosure relates to methods for treating or alleviating a fetal alcohol spectrum disorder (FASD) in a subject, the method comprising administering to the subject an effective amount of an apolipoprotein E (APOE)-modulating therapeutic, thereby treating or alleviating the FASD.
Resumen de: WO2026137685A1
The present application relates to the technical field of immunochromatography, and in particular, to a test strip for detecting β-amyloid protein and the use thereof. In the present application, colored microspheres are conjugated to a β-amyloid monoclonal antibody via covalent bonds, and then the conjugate is coated onto a conjugate pad. Compared with colloidal gold, the colored microspheres exhibit greater stability and higher sensitivity. Additionally, the colored microspheres feature bright and diverse colors, uniform particle sizes, good monodispersity, and strong reproducibility of detection results. The test strip provided by the present application has the advantages of simplicity, rapidity and high timeliness, requires no additional reagents, instruments and professional personnel, and supports on-site operation. By means of simply applying a to-be-detected sample to a sample loading port of the test strip, a detection result can be interpreted within 15 min. The result interpretation is visual, intuitive, accurate and straightforward, with a low risk of human errors such as false positives and false negatives.
Resumen de: WO2026141950A1
The present application provides: a spectroscopic analysis substrate for diagnosing dementia, comprising a hydrophilized graphene layer; and a spectroscopic device comprising same. More specifically, the present application provides: a spectroscopic analysis substrate for diagnosing dementia, having improved accuracy due to increased binding force and selectivity for amyloid beta, the substrate comprising a hydrophilized graphene layer; and a spectroscopic device comprising the spectroscopic analysis substrate.
Resumen de: AU2024388318A1
The present disclosure provides precision medicine or personalized therapy of using a Sigma-1 receptor agonist in treating neurological disease or disorder. The precision medicine or personalized therapy involves patient selection through differentially expressed genes or affected biological pathways related to the Sigma-1 receptor agonist therapy. Also provided are kits for practicing the methods.
Resumen de: US20260185993A1
0000 A functional peptide modified magnetic composite nanobead, and a method and an application thereof for detecting β-secretase (BACE1) and screening its inhibitors are provided. The chemical composition of the magnetic composite nanobead is: ferroferric oxide (Fe<3>O<4>) nanoclusters used as magnetic cores, the surface of the magnetic cores coated with a silica shell, the surface of the shell connected with an ethylene diamine tetraacetic acid (EDTA) modification layer, and Co<2+> or Ni<2+> ions chelated on the EDTA layer, and the Cy5 fluorescein labeled functional peptide coated on the surface of magnetic composite nanobead by the interaction between Co<2+> or Ni<2+> ions and hexahistidine-tag.
Resumen de: US20260185056A1
An in vitro method of producing a fused tissue culture with at least three different tissues including selecting a spatial shape for attaching the at least three different tissues to each other, placing the at least three different tissues into contact in the spatial shape, culturing the at least three different tissues under conditions that maintains tissue fusion of the at least three different tissues is disclosed. Further provided is a tissue culture comprising a planar or linear fusion of at least three different neural or neuronal tissues, uses thereof and means for its production.
Resumen de: US20260187803A1
0000 Integrated platforms, systems, and associated processes for measuring lifespan, body size and shape, activity, pathology, pigmentation/color, and multiple in vivo molecular biomarkers using multiple cameras are described. The integrated platform includes a plate and trays supported on the plate. Each tray can hold animals. The integrated platform also includes an imaging module with a first camera and a second camera. The first camera can capture first images associated with movement of the animals and the second camera can capture second images and third images associated with biomarkers of the animals.
Resumen de: US20260184770A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Nº publicación: US20260185138A1 02/07/2026
Solicitante:
TETMEDICAL INC [US]
TETmedical, Inc.
Resumen de: US20260185138A1
0000 A coupled tethered enzyme luminescence assay for measuring the amount of enzymatic activity of neural specific enolase in a liquid blood sample taken from a patient. The assay has a test well and a positive control well. The test well has a number of components including an inhibitor and a number of first tethered enzyme nanobots formed by tethering pyruvate kinase enzyme to silica nanoparticles, and a number of second enzyme nanobots formed by tethering luciferase molecules to silica nanoparticles for oriented immobilization of the tethered enzymes pyruvate and luciferase. The pyruvate kinase and luciferase enzymes have two differing types of affinity tags. One type of affinity tag facilitates extraction of enzymes from a liquid and another affinity tag for tethering to a silica nanoparticle. The positive control well includes the components of the test well and an added preset amount of enolase enzyme.
BOPI
Sede Electrónica
